Medable Reaches $2.1B Valuation as Tiger, Blackstone, GSR Pump New Capital into Clinical Trials

Medable, a patient-focused clinical research company offering a cloud option for adoption of digital and decentralized clinical trials, brought in a new capital infusion of $304 million in Series D funding — its fourth round since 2020 — to give it a valuation of $2.1 billion.

Medable’s software as a service connects patients, trial sites and clinical trial teams to streamline the design, recruitment, retention and data quality of trials in a way that makes them accessible to anyone anywhere.

The funding round was co-led by new investors Blackstone Growth and Tiger Global and existing investor GSR Ventures. It also included follow-on investment from existing investors Sapphire Ventures and WTI.

“It’s great to see more mainstream investors interested in the space,” Dr. Michelle Longmire, CEO and co-founder of Medable, told TechCrunch. “It adds momentum to what we are going after.”